PL372695A1 - Środek leczniczy do leczenia chorób wymagających hamowania lub zmniejszania aktywności protein transportujących diwęglany, regulujących wartość pH - Google Patents

Środek leczniczy do leczenia chorób wymagających hamowania lub zmniejszania aktywności protein transportujących diwęglany, regulujących wartość pH

Info

Publication number
PL372695A1
PL372695A1 PL03372695A PL37269503A PL372695A1 PL 372695 A1 PL372695 A1 PL 372695A1 PL 03372695 A PL03372695 A PL 03372695A PL 37269503 A PL37269503 A PL 37269503A PL 372695 A1 PL372695 A1 PL 372695A1
Authority
PL
Poland
Prior art keywords
medicament
regulating
activity
reduction
treatment
Prior art date
Application number
PL03372695A
Other languages
English (en)
Inventor
Heinz Rupp
Bernd Eisele
Dieter Ziegler
Bodo Jäger
Bernhard Maisch
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Publication of PL372695A1 publication Critical patent/PL372695A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03372695A 2002-06-19 2003-06-16 Środek leczniczy do leczenia chorób wymagających hamowania lub zmniejszania aktywności protein transportujących diwęglany, regulujących wartość pH PL372695A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02013387 2002-06-19

Publications (1)

Publication Number Publication Date
PL372695A1 true PL372695A1 (pl) 2005-07-25

Family

ID=29797127

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372695A PL372695A1 (pl) 2002-06-19 2003-06-16 Środek leczniczy do leczenia chorób wymagających hamowania lub zmniejszania aktywności protein transportujących diwęglany, regulujących wartość pH

Country Status (6)

Country Link
US (1) US7309706B2 (pl)
EP (1) EP1517688A2 (pl)
AU (1) AU2003257418A1 (pl)
CA (1) CA2487541A1 (pl)
PL (1) PL372695A1 (pl)
WO (1) WO2004000312A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537898T3 (es) * 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
WO2008133273A1 (ja) * 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
PH12013500242A1 (en) * 2008-06-13 2013-04-08 Shionogi & Co Sulfur-containing heterocyclic derivative having b-secretase-inhibiting activity
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8338421B2 (en) 2008-08-01 2012-12-25 Alpha Synergy Development, Inc. Compositions and methods for reversing rebound hyperemia
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
EP2360155A4 (en) * 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
JPWO2012147763A1 (ja) 2011-04-26 2014-07-28 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
CN110358723A (zh) * 2019-05-08 2019-10-22 广州医科大学附属第二医院 一种成年小鼠心脏成纤维细胞的培养方法
EP3735974A1 (en) * 2019-05-10 2020-11-11 Rottapharm Biotech S.r.l. Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease
KR102398219B1 (ko) * 2020-02-07 2022-05-17 주식회사 뉴로벤티 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
KR20250145285A (ko) * 2024-03-28 2025-10-13 건국대학교 글로컬산학협력단 릴메니딘을 포함하는 정서장애의 예방, 개선 또는 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1453703A (en) * 1972-12-28 1976-10-27 Science Union & Cie Substituted cyclopropylmethylamines processes for their preparation and pharmaceutical compositions containing them
US4102890A (en) * 1972-12-28 1978-07-25 Science-Union Et Cie, Societe Francaise De Recherche Medicale 2-Amino oxazolines and process for making the same
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE2849537C2 (de) 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
FR2707984B1 (fr) * 1993-07-23 1995-09-01 Adir Nouvelles pipérazines substituées, leur procédé de préparation et les compositions les contenant.
ES2186720T3 (es) * 1994-05-27 2003-05-16 Merck & Co Inc Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
FR2726558B1 (fr) 1994-11-03 1996-12-06 Adir Nouvelles 5-(aryloxymethyl) oxazolines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2733685B1 (fr) * 1995-05-05 1997-05-30 Adir Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant
US5804587A (en) * 1995-06-29 1998-09-08 The Procter & Gamble Company 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
FR2756560A1 (fr) * 1996-12-04 1998-06-05 Adir Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE201598T1 (de) * 1997-09-16 2001-06-15 Solvay Pharm Gmbh Verwendung von moxonidin zur behandlung neuropathischer schmerzen
US6117879A (en) * 1997-09-16 2000-09-12 Solvay Pharmaceuticals Gmbh Methods of using moxonidine to inhibit nociceptive pain
DE69830114D1 (de) * 1997-09-16 2005-06-16 Solvay Pharm Gmbh Analgetische Zusammensetzung welche Moxonidine und ein Opioid-Analgetika enthält
AU4919099A (en) * 1998-07-11 2000-02-01 University Of Bristol, The Compounds having activity at imidazoline receptors
US6777394B1 (en) * 1998-07-15 2004-08-17 George D. Prell Methods and compositions for regulating imidazoline receptors
DE19911371A1 (de) * 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
US6475752B1 (en) * 1999-07-30 2002-11-05 Incyte Genomics, Inc. Mammalian imidazoline receptor
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
FR2801051B1 (fr) 1999-11-17 2001-12-14 Adir Nouveaux composes aminopyrroline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9929216D0 (en) 1999-12-11 2000-02-02 Univ Bristol Isoquinoline and Quinoline Containing substances
AU2001283440A1 (en) * 2000-08-18 2002-03-04 Bristol-Myers Squibb Company Novel imidazoline receptor homologs
DE10052524A1 (de) * 2000-10-23 2002-04-25 Beko Technologies Gmbh Filter zum Abscheiden von Fremdstoffen aus einem Gasstrom
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing

Also Published As

Publication number Publication date
CA2487541A1 (en) 2003-12-31
WO2004000312A2 (de) 2003-12-31
EP1517688A2 (de) 2005-03-30
US20050165080A1 (en) 2005-07-28
WO2004000312A3 (de) 2004-02-19
AU2003257418A1 (en) 2004-01-06
US7309706B2 (en) 2007-12-18

Similar Documents

Publication Publication Date Title
PL372695A1 (pl) Środek leczniczy do leczenia chorób wymagających hamowania lub zmniejszania aktywności protein transportujących diwęglany, regulujących wartość pH
AU2003270903A8 (en) A video game for assisting healing of the human body
IL169161A0 (en) Disease treatment via antimicrobial peptide inhibitors
AU2003220317A8 (en) Methods and drug delivery systems for the treatment of orofacial diseases
IL164784A0 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
AU2003225160A8 (en) "biosensor for dialysis therapy"
EP1572101A3 (en) Disease treatment via antimicrobial peptide inhibitors
AU2003285091A8 (en) Interferon antagonists useful for the treatment of interferon related diseases
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
EP1500401A4 (en) DRUGS FOR THE TREATMENT OF VASCULAR DISEASES
GB0216972D0 (en) Peptides and peptide derivaties for the treatment of &-synuclein-related diseases
AU2003232148A8 (en) A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
PL375584A1 (pl) Leczenie terapeutyczne
EP1471932A4 (en) USE OF A POLYPEPTIDE FOR THE TREATMENT OF PRURITUS IN ANIMALS
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
AU2003223780A8 (en) Treatment for pompe disease
AU9545701A (en) Use of carp inhibitors for the treatment of heart diseases
AU2003263036A8 (en) Span-xb gene and protein for the diagnosis and treatment of cancer
AU2003240746A8 (en) Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
GB0201025D0 (en) The treatment of degenerative diseases
IL163553A0 (en) Microorganism for genetic therapeutic treatment ofproliferative diseases
AU2003215384A1 (en) Microdispersion treatment of a protein or pharmaceutical
AU2003217432A8 (en) Angiopoietin-1 in the treatment of disease
AU2003295504A8 (en) Development of therapeutics for the treatment of endotoxin-mediated diseases

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)